Search

Your search keyword '"Yosifova A"' showing total 317 results

Search Constraints

Start Over You searched for: Author "Yosifova A" Remove constraint Author: "Yosifova A"
317 results on '"Yosifova A"'

Search Results

1. IGHV Mutational Status in a Cohort of Bulgarian CLL Patients: High Unmutated CLL Prevalence in North-East Bulgaria

2. EFFECTS OF MLS-LASER ON NEUROPATHIC PAIN IN DIABETIC SENSОMOTOR NEUROPATHY

5. The globalizability of temporal discounting

7. Natural products for the treatment of allergic rhinitis: focus on cellular signaling pathways and pharmacological targets.

9. Methods and Means for Analyzing Heat-Loss in Buildings for Increasing Their Energy Efficiency

15. The general fault in our fault lines

16. MANAGEMENT OF ANTHROPOGENIC TOURIST RESOURCES - A KEY FACTOR FOR SUSTAINABLE DEVELOPMENT OF BULGARIAN TOURISM

18. Project Management & Digitalization : An Explorative Case Study About Challenges for Project Managers in Consultancy Firms

20. Education and behavior1

22. Replicating patterns of prospect theory for decision under risk

23. Primo Levi. Su legado humanista

26. Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

27. Supplementary Figure S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

28. Data from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

31. The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection

32. The effects of supplementation with Cynara scolymus L. on anthropometric indices: А systematic review and dose-response meta-analysis of clinical trials

33. Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension

34. Special aspects of the reporting of capital in the budgetary entities

35. Credit risk disclosure in the annual financial statements of Bulgarian banks

37. Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

38. STATISTICAL DEPENDENCIES BETWEEN NON-FINANCIAL DISCLOSURES AND EX-POST FINANCIAL PERFORMANCE IN THE BULGARIAN ROAD FREIGHT TRANSPORTATION INDUSTRY.

40. New expected loss impairment model – a challenge for the banks in Bulgaria

41. Administrative rights and obligations of the patient

42. The globalizability of temporal discounting

46. MLS laser in diabetic sensorimotor polyneuropathy—late effects

47. The Neuroprotective Effects of Astaxanthin: Therapeutic Targets and Clinical Perspective

48. Initial research for passive and energy efficient building awareness in Bulgaria

49. Controlled High-Temperature Sintering of Boron Carbide

Catalog

Books, media, physical & digital resources